Navigation Links
Atherotech to Exhibit the VAP Test at Internal Medicine 2008

VAP expanded cholesterol test can help clinicians identify best treatment

options for patients at risk of heart disease

BIRMINGHAM, Ala., May 8 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP Cholesterol Test in booth No. 2123 at the American College of Physicians (ACP) Internal Medicine 2008, the premier scientific meeting for internal medicine. The annual meeting takes place May 13-17, 2008, at the Washington Convention Center in Washington, D.C.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease -- or who are already taking cholesterol lowering medication -- are candidates for the comprehensive VAP (Vertical Auto Profile) Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with Triglycerides > 150, HDL < 40, LDL >130, Total Cholesterol > 200) should also opt for the more detailed VAP Test.

The VAP(R) Cholesterol Test (Atherotech, Inc.) is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the recent expert consensus guidelines from the American Diabetes Association and American College of Cardiology.

Atherotech representatives will be available to discuss the VAP expanded cholesterol test in booth No. 2123, and blood draws will be provided to qualified attendees. Test results will be returned via mail after the conference.

The VAP Test is the most accurate and comprehensive cholesterol test available today, measuring 15 separate components of blood cholesterol as opposed to three in a standard test. The comprehensive test can identify more than twice the number of lipid abnormalities (the No. 1 risk factor of heart disease) than the standard cholesterol test, and is the only cholesterol test to identify markers for Metabolic Syndrome, a precursor for diabetes.

The VAP Test is available nationwide. For more information call 877.901.8510 or visit

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP Technology. The VAP Test directly measures the cholesterol content of all lipids, components and subclasses. It is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations calling for more accurate, direct low-density lipoprotein (LDL) measurement, which is unaffected by triglycerides. The VAP Cholesterol Test -- the new standard of care for patients at risk for cardiovascular disease -- is available through national and regional diagnostic laboratories and is reimbursed by most payers as well as Medicare. For more information, visit

SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
2. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
3. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Quest International Announces They Will be First in US to Exhibit True 12-Bit Grayscale Mammographic Images
6. ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
7. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
8. Biotechnology Leader to Exhibit at Upcoming Trade Show
9. BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
10. West Michigan Science & Technology Initiative Seeks Exhibitors for Annual Life Science Showcase
11. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for Pharmaceutical Engineering ... premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place ... the largest number of attendees in more than a decade. , “The ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... SHPG ) announced today that Jeff ... 27 th Annual Healthcare Conference in New York ... a.m. EST (1:30 p.m. GMT). --> SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology:
(Date:11/20/2015)... 20, 2015 NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... , was recently interviewed on The RedChip Money ... this weekend on Bloomberg Europe , Bloomberg Asia, ... --> NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its in-depth ... Sullivan recognizes BIO-key with the 2015 Global Frost & ... Frost & Sullivan presents this award to the company ... to the needs of the market it serves. The ... meets and expands on customer base demands, the overall ...
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
Breaking Biology News(10 mins):